Annual Epidemiology & Surveillance Report

Data Through December 2018

District of Columbia Department of Health
HIV/AIDS, Hepatitis, STD, and TB Administration (HAHSTA)
Acknowledgments

This report was compiled through the combined efforts of many individuals in DC Health’s HIV/AIDS, Hepatitis, STD, and Tuberculosis Administration, with contribution from the Milken Institute School of Public Health at George Washington University. This report would not have been possible without the hard work, dedication, and contribution of health care providers, community groups, researchers, and members of the community.

Muriel Bowser, Mayor
Rashad M. Young, City Administrator
LaQuandra S. Nesbitt, MD, MPH, Director, DC Health
Michael Kharfen, Senior Deputy Director

With special thanks to:
- Strategic Information Division
- STD/TB Control Division
- GWU Milken Institute School of Public Health

The Annual Epidemiology & Surveillance Report is compiled by the Strategic Information Division. To request additional data or aid in interpreting the data herein, contact:

Strategic Information Division
HIV/AIDS, Hepatitis, STD, and TB Administration (HAHSTA)
Government of the District of Columbia
DC Health
899 N. Capitol St. NE
Fourth Floor
Washington, DC 20002

Phone: (202) 671-4900

This report is available online at: https://dchealth.dc.gov/publication/hahsta-annual-epidemiology-surveillance-report-2019

## Contents

Executive Summary 3  
HIV Cases Living in DC 6  
Newly Diagnosed HIV Cases 8  
Perinatal HIV 9  
HIV Incidence 9  
HIV Care Dynamics 10  
Ryan White Care Dynamics 12  
Transmitted Drug Resistance 13  
HIV Mortality 14  
Sexually Transmitted Infections 15  
Chlamydia 15  
Gonorrhea 16  
Syphilis 17  
Viral Hepatitis 18  
Hepatitis B 18  
Hepatitis C 19  
Tuberculosis 21  
HIV Special Populations 22  
Women 22  
Men who have Sex with Men 23  
People Who Inject Drugs (PWID) 24  
Transgender People 25  
Older Adults (Aged 55 and older) 26  
Latinos 27  
Youth (Aged 13-24) 28  
Foreign-born 30  
National HIV Behavioral Surveillance Study (NHBS) 31  

Appendix A – Understanding Surveillance Data 32  
Understanding HIV Surveillance 32  
Understanding the District of Columbia HIV Prevalence Estimate 32  
Understanding the HIV Incidence Estimate 35  
Understanding Clinical Outcomes 36  
Understanding HIV-Related Drug Resistance 36  
Understanding Sexually Transmitted Infections (STI) Surveillance 37  
Understanding Viral Hepatitis Surveillance 37  
Understanding Tuberculosis Surveillance 38  
Incomplete Reporting/Missing Data 38
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B1</td>
<td>People Living with HIV in the District of Columbia as of December 31, 2018, by Gender Identity, Current Age, Race/Ethnicity and Mode of Transmission.</td>
</tr>
<tr>
<td>B2</td>
<td>People Living with HIV in the District of Columbia as of December 31, 2018, by Gender Identity and Mode of Transmission.</td>
</tr>
<tr>
<td>B5</td>
<td>Newly Diagnosed HIV Cases by Year of Diagnosis, Gender Identity, Race/Ethnicity, Mode of Transmission, and Age at Diagnosis, District of Columbia, 2014-2018.</td>
</tr>
<tr>
<td>B7</td>
<td>Newly Diagnosed HIV Cases by Year of Diagnosis, Gender Identity, and Age at Diagnosis, District of Columbia, 2014-2018.</td>
</tr>
<tr>
<td>B12</td>
<td>2018 Ryan Care Dynamics, by Gender Identity, Race, Ethnicity, Mode of Transmission and Current Age, District of Columbia.</td>
</tr>
<tr>
<td>B14</td>
<td>Number and Rate per 100,000 persons of Chlamydia Cases by Year of Diagnosis, Gender, Age, and Ward, District of Columbia, 2014-2018.</td>
</tr>
<tr>
<td>B15</td>
<td>Number and Rate per 100,000 persons of Gonorrhea Cases by Year of Diagnosis, Gender, Age, and Ward, District of Columbia, 2014-2018.</td>
</tr>
<tr>
<td>B16</td>
<td>Number and Rate per 100,000 persons of Primary and Secondary Syphilis Cases by Year of Diagnosis, Gender Identity, Race/Ethnicity, Age, and Ward, District of Columbia, 2014-2018.</td>
</tr>
<tr>
<td>B18</td>
<td>Number and Rate per 100,000 persons of Newly Reported Chronic Hepatitis B Cases by Gender, Age at Diagnosis, and Year of Diagnosis, District of Columbia 2014-2018.</td>
</tr>
<tr>
<td>B19</td>
<td>All Positive Chronic Hepatitis C Cases by Gender, Age at Diagnosis, Case Classification, and Diagnosis Type, District of Columbia 2014-2018.</td>
</tr>
<tr>
<td>B20</td>
<td>Number and Rate per 100,000 persons of Newly Reported Chronic Hepatitis C Cases by Gender, Age at Diagnosis, and Year of Diagnosis, District of Columbia 2014-2018.</td>
</tr>
</tbody>
</table>
Executive Summary

The Annual HIV, Sexually Transmitted Infections (STIs), Hepatitis, and Tuberculosis (TB) Surveillance Report for the District of Columbia shows the District continues to experience complex epidemics of HIV, STIs, hepatitis, and TB. The Department of Health (DC Health) reports that the number of new HIV cases decreased slightly for the second year, which highlights the urgency to accelerate key prevention and treatment strategies. The District maintained high rates of STIs and level number of new TB cases. There are encouraging advances in more people being diagnosed and treated to cure for hepatitis C.

Figure 1. Newly Diagnosed HIV Disease Cases, Deaths, and Living HIV Cases, by Year, District of Columbia, 1983-2018.

Key points in this surveillance update of the District epidemics in the year 2018 include:

- 12,322 current residents of the District of Columbia or 1.8% of the population are living with HIV.
- The number of newly diagnosed HIV cases in the District decreased to 360 cases in 2018, a decline of 49% from 721 cases in 2011 and 73% from 1,374 cases in 2007.
- There were no babies born with HIV in 2018.
- The number of newly diagnosed HIV cases attributable to injection drug use decreased by 94% from 150 cases in 2007, prior to the scale up of DC’s needle exchange program, to 9 cases in 2018; however, the number of men newly diagnosed with HIV attributable to injection drug use increased for the first time in 10 years from 2 in 2017 to 7 in 2018.
- Blacks and Latinos with HIV exceeded 1% of their respective populations, with Blacks disproportionately impacted at 2.7%.
- For the first time, more than half of people living with HIV in DC are older than 50 years old.
• Young people ages 13 to 24 represent 20% of new HIV diagnoses; the number of new HIV diagnoses among young people ages 20-24 remained level for the past three years.
• Sexual contact is the leading mode of transmission reported among newly diagnosed and identified HIV cases.
• There were 9,007 cases of chlamydia, 4,249 cases of gonorrhea and 282 cases of primary and secondary syphilis reported.
• A substantial minority (39%) of primary and secondary syphilis cases occurred among people with HIV.
• There were 1,515 people with newly reported hepatitis C in 2018.
• There were 36 cases of TB in 2018 with three-quarters among people born outside of the US.

HIV Care Continuum
DC Health tracks the District’s efforts to improve the care continuum for people living with HIV to sustain their health from diagnosis to linkage and retention in care. The care continuum measures people linked to care, engaged in care, and viral load suppression. Surveillance data includes all people known to be living in the District. DC Health administers the Ryan White CARE Program that serves more than half of all people living with HIV in the District. People achieving viral suppression maintain strong immune systems, achieve healthier outcomes, and cannot transmit HIV sexually to other people, known as Undetectable equals Untransmittable or U=U. The District saw improvements in the care continuum in DC through 2018:

• Among people newly diagnosed with HIV, 57% were linked to medical care within 7 days of diagnosis and 84% within 30 days.
• Viral suppression among all people living with HIV in DC remained at 66% overall and 85% among people with an indication of engaged in care.
• There was an increase in achieving viral suppression within six months of new diagnosis from 63% to 68% from 2017 to 2018, where the median time to viral suppression was 114 days. This indicates that people are getting on HIV treatment quicker.
• Among Ryan White clients, 73% retained were in care, 95% prescribed treatment, and 80% virally suppressed.
• Young people ages 0-19 and 20-24 had the lowest viral suppression rates at 40.7% and 50.9%, respectively; among newly diagnosed people, viral suppression rates were lowest for people who inject drugs at 42.6%.

Scaling Up Success
The District Government and its community partners continue to scale up programs to reduce the impact of HIV, STDs, hepatitis and TB on residents of Washington, DC. These successes are the most recent achievements by the District.

• Supported 61,584 HIV tests in 2018; 44% of the tests were among young people ages 13 to 29.
• Distributed more than 4.1 million male and female condoms in 2018.
• Supported about 3,400 people to start Pre-Exposure Prophylaxis (PrEP) to prevent HIV in 2018.
• Removed 530,527 needles from the street in 2018 through the DC needle exchange programs.
• Provided 5,000 free STD tests for young people through the school based STD screening and community screening programs in 2018.
• Provided HIV medical care and support services to more than 7,000 people through the Ryan White Program.

Ending the HIV Epidemic
In 2016, Mayor Bowser released the 90/90/90/50 Plan to End the HIV Epidemic in the District of Columbia by 2020. While there has been steady progress (see Table E1), this year’s report reflects the necessity to increase availability, accessibility, and acceptability of services. In 2019, the US Department of Health and Human Services launched an Ending the HIV Epidemic Initiative, which focuses on 48 counties, seven rural states, and two cities (Washington, DC and San Juan, PR) where half of all new HIV diagnoses are located nationally. DC Health with its public-private collaborators DC Appleseed Center and Washington AIDS Partnership aims to update the 90/90/90/50 Plan to achieve
a compatible and timely end to the epidemic in the nation's capital.

**Table E1.** HIV Wellness and Prevention Measures of the 90-90-90-50 Plan, 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Goal #1: 90% of HIV-positive District residents know their status</td>
<td>86%</td>
<td>86%</td>
<td>87%</td>
<td>pending</td>
<td>90%</td>
</tr>
<tr>
<td>Goal #2: 90% of District Residents living with HIV are in treatment</td>
<td>73%</td>
<td>76%</td>
<td>77%</td>
<td>78%</td>
<td>80%</td>
</tr>
<tr>
<td>Goal #3: 90% of District residents living with HIV who are in treatment reach viral suppression</td>
<td>78%</td>
<td>82%</td>
<td>84%</td>
<td>85%</td>
<td>90%</td>
</tr>
<tr>
<td>Goal #4: 50% reduction in new HIV diagnoses</td>
<td>400</td>
<td>378</td>
<td>373</td>
<td>360</td>
<td>260*</td>
</tr>
</tbody>
</table>

*Reference year 2013
HIV Cases Living in DC

In 2016, this report, for the first time, devised a methodology to more accurately count the number of people diagnosed with HIV actually living in the District as compared to previous reports that contained data of the cumulative number of known living individuals diagnosed with HIV who were residents of the District at the time of diagnosis. The new methodology is repeated here. As presented in Figure 1, the number of all diagnosed stands at 17,830. Figure 1 accounts for new HIV diagnoses among current District residents, reported deaths among those previously diagnosed, and the residential migration of HIV positive individuals in and out of the District over time. The report uses residence at last lab to more accurately assess the number of individuals diagnosed with HIV living within the District (Figure 1). This methodology not only provides a better foundation for understanding the extent of HIV within the District, but also an improved baseline from which to evaluate the population coverage of HIV prevention and care activities.

Figure 1. People Living with HIV in the District of Columbia as of December 31, 2018

Estimation of the Number of People Living in DC

Of the 17,830 individuals diagnosed with HIV while a District resident, approximately 43% (n=7,579) were presumed to have moved outside of the jurisdiction (out-migration) prior to the end of 2018, as evidenced by a non-District residential address on their last reported laboratory report or the lack of any reported laboratory information for more than 5 years. Laboratory data was also used to assess the number of individuals diagnosed with HIV while a resident of other jurisdictions who have moved into the District over time (in-migration); we identified 1,984 individuals initially diagnosed with HIV outside of the jurisdiction with a current residential address in the District. As indicated in Figure 1, after adjusting the initial count of all living HIV cases for in- and out-migration, an estimated 12,322 individuals diagnosed with HIV were presumed to be living in the District at the end of 2018. Detailed characteristics of people living with HIV based on residential migration status since diagnosis are included in appendix tables B1-B4.
future, HAHSTA expects to refine the estimates further, as a result of improved data-sharing processes with surrounding jurisdictions and additional information sources for ascertainment of residential addresses.

**Proportion of HIV Cases Living in DC, by Race/Ethnicity, Gender Identity and Mode of Transmission, District of Columbia, 2018**

- **Black MSM and MSM/IDU**: 27%
- **Black Heterosexual Men**: 8%
  - **Black Men Other/RNI**: 6%
  - **Black Men IDU**: 5%
- **Black Heterosexual Women**: 15%
  - **Black Women Other/RNI**: 4%
- **White MSM and MSM/IDU**: 13%
  - **White Men Other**: 2%
- **Latino MSM and MSM/IDU**: 5%
  - **Latino Male Other**: 1%
- **Other**: 5%
  - **Black Transgender**: 1%
  - **Other Transgender**: 5%
  - **Latina Woman**: 1%
  - **White Woman**: 3%

**Proportion of Residents Living with HIV by Race/Ethnicity and Gender Identity, District of Columbia, 2018**

- **White Females**: 0.1%
- **Latina Females**: 0.3%
- **White Males**: 1.5%
- **Black Females**: 1.6%
- **Latino Males**: 2.1%
- **Black Males**: 3.8%

**Rate of HIV Cases Living in the District by Census Tract, District of Columbia, 2018 (N=12,322*)**

**Rate of HIV per 100,000 persons**

- 0-933.2
- 933.3-1,850.7
- 1,850.8-2,587.5
- 2,587.6-3,389.2
- 3,389.3-4,927.1

*3% of cases had a missing address or an address that did not geocode and were not included in this map. Though not included in this map, 51 cases were in jail and 79 cases were homeless*

Rates were calculated using the 2017 Census Estimates
Newly Diagnosed HIV Cases

Rates were calculated using the 2017 Census Estimates. Please refer to appendix table B5-B7 for additional data regarding newly diagnosed HIV cases.
Perinatal HIV

Perinatal HIV cases are defined as those in which transmission occurs during pregnancy, labor and delivery, or breastfeeding. Since the introduction of recommendations to provide anti-retroviral medication to women during pregnancy, during labor and delivery, and to the infant in the neonatal period, there has been a 95% reduction in mother to child transmission of HIV nationally. Transmission rates among those who receive recommended treatment during pregnancy, at labor and delivery, and newborn period are as low as 1%.

Figure 2. Perinatal HIV cases by Year of Birth, District of Columbia, 2007-2018

HIV Incidence

Figure 3. Estimated Number of Newly Infected HIV Cases by Year, District of Columbia, 2014-2018

The estimated number of new infections of HIV in the District remained stable from 2014 to 2018. The estimated rate of new infections in the District exceeded the national rate in 2015 at 47.6 estimated cases/100,000 compared with 14.4 estimated cases/100,000 respectively. Since the number of new infections of HIV is an estimate, the 95% confidence interval shows the range within which the estimate may lie after adjusting for variability in sampling and timing of testing.
HIV Care Dynamics

The Care Continuum is the approach of diagnosing people with HIV, linking them into care and treatment, retaining them in care and medication adherence, and achieving viral load suppression, which is the marker of a person’s and community’s health. Assessing HIV care dynamics is an essential step in understanding the strengths of HIV programs in the District, as well as an opportunity to identify and resolve gaps in the care continuum.

2018 Care Dynamics among People Living with HIV in DC

- Living in DC in 2017: 12,078
- Ever linked to HIV care: 11,875 (98% ever linked)
- Retained in any care in 2018: 9,381
  - 1 medical visit: 29%
  - >1 medical visit: 71%
- Virally suppressed in 2018: 7,950 (60% suppressed)

Retention in Any HIV Care among HIV Cases Living in DC, by Gender Identity, District of Columbia, 2018. N=12,078

- Transgender: 82%
- Female: 85%
- Male: 76%

Stage of Disease at First Lab in DC and in 2018 among Cases Living in DC, District of Columbia, N=12,078

- Stage 1: 33%
- Stage 2: 33%
- Stage 3: 21%
- Unknown: 7%

57.2% were linked to HIV care within 7 days of diagnosis

114.0 the median number of days to viral suppression

Please refer to appendix table B8 for additional data regarding HIV care dynamics.
Please refer to appendix table B8-11 for additional data regarding HIV care dynamics.
HIV Care dynamics among clients served through Ryan White in the District was examined to evaluate clients on the care continuum and assess their health outcomes. This continuum of care differs from what has been previously presented in several ways. First, the population used is a subset of the total number of HIV cases living in the District. These cases are not newly diagnosed in a given year, but are HIV cases who received any type of Ryan White CARE Act funded medical service in 2018. Second, care status was measured through documented medical visits, rather than laboratory tests. Finally, information is included on the number of clients who had been prescribed HIV medication.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clients with one or more medical visit</td>
<td>Ryan White clients with at least one documented primary care visit in 2018</td>
</tr>
<tr>
<td>Retained in care in 2017</td>
<td>Having 2 or more medical visits in 2018 that were at least 90 days apart</td>
</tr>
<tr>
<td>Prescribed ART</td>
<td>Ryan White clients with documentation of having been prescribed HIV medication</td>
</tr>
<tr>
<td>Virally suppressed in 2017</td>
<td>Having a viral load result of &lt;200 copies/mL at the most recent viral load test in 2018</td>
</tr>
</tbody>
</table>

Please refer to appendix table B12 for additional data regarding RW HIV care dynamics.
Transmitted Drug Resistance

Table 2. Evidence of Antiretroviral Drug Resistance among Newly Diagnosed HIV Cases with Initial Genotype Sequences Collected within 90 days of Diagnosis, District of Columbia, 2014-2018

<table>
<thead>
<tr>
<th>Antiretroviral Drug Classification</th>
<th>Antiretroviral Drug (ARV)</th>
<th>High-Level Resistance %</th>
<th>Intermediate Resistance %</th>
<th>Low-Level Resistance %</th>
<th>Susceptible %</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Integrase Strand Transfer Inhibitors</strong></td>
<td>Bictegravir</td>
<td>0.0</td>
<td>0.4</td>
<td>0.0</td>
<td>99.6</td>
<td>227</td>
</tr>
<tr>
<td></td>
<td>Dolutegravir</td>
<td>0.0</td>
<td>0.4</td>
<td>0.0</td>
<td>99.6</td>
<td>227</td>
</tr>
<tr>
<td></td>
<td>Elvitegravir</td>
<td>0.9</td>
<td>0.0</td>
<td>1.3</td>
<td>97.8</td>
<td>227</td>
</tr>
<tr>
<td></td>
<td>Raltegravir</td>
<td>0.4</td>
<td>0.4</td>
<td>1.3</td>
<td>97.8</td>
<td>227</td>
</tr>
<tr>
<td><strong>Non-Nucleotide Reverse Transcriptase Inhibitors</strong></td>
<td>Doravirine</td>
<td>1.1</td>
<td>2.3</td>
<td>5.4</td>
<td>91.2</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Efavirenz</td>
<td>9.6</td>
<td>2.1</td>
<td>0.7</td>
<td>87.6</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Etravirine</td>
<td>1.0</td>
<td>1.1</td>
<td>0.7</td>
<td>97.2</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Nevirapine</td>
<td>10.6</td>
<td>1.7</td>
<td>0.8</td>
<td>86.9</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Rilpivirine</td>
<td>2.4</td>
<td>0.6</td>
<td>4.1</td>
<td>92.9</td>
<td>831</td>
</tr>
<tr>
<td><strong>Nucleotide Reverse Transcriptase Inhibitors</strong></td>
<td>Abacavir</td>
<td>0.6</td>
<td>0.7</td>
<td>2.3</td>
<td>96.4</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Didanosine</td>
<td>0.6</td>
<td>1.1</td>
<td>0.8</td>
<td>97.5</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Emtricitabine</td>
<td>2.7</td>
<td>0.0</td>
<td>0.0</td>
<td>97.4</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Lamivudine</td>
<td>2.7</td>
<td>0.0</td>
<td>0.0</td>
<td>97.4</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Stavudine</td>
<td>0.6</td>
<td>1.2</td>
<td>1.8</td>
<td>96.4</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Tenofovir</td>
<td>0.1</td>
<td>0.7</td>
<td>1.0</td>
<td>98.2</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>Zidovudine</td>
<td>0.6</td>
<td>1.1</td>
<td>1.3</td>
<td>97.0</td>
<td>831</td>
</tr>
<tr>
<td><strong>Protease Inhibitors</strong></td>
<td>Atazanavir/r</td>
<td>0.4</td>
<td>0.1</td>
<td>0.8</td>
<td>98.7</td>
<td>845</td>
</tr>
<tr>
<td></td>
<td>Darunavir/r</td>
<td>0.0</td>
<td>0.2</td>
<td>0.2</td>
<td>99.5</td>
<td>845</td>
</tr>
<tr>
<td></td>
<td>Fosamprenavir/r</td>
<td>0.4</td>
<td>0.2</td>
<td>0.7</td>
<td>98.7</td>
<td>845</td>
</tr>
<tr>
<td></td>
<td>Indinavir/r</td>
<td>0.2</td>
<td>0.7</td>
<td>0.4</td>
<td>98.7</td>
<td>845</td>
</tr>
<tr>
<td></td>
<td>Lopinavir/r</td>
<td>0.0</td>
<td>0.6</td>
<td>0.6</td>
<td>98.8</td>
<td>845</td>
</tr>
<tr>
<td></td>
<td>Nelfinavir</td>
<td>1.1</td>
<td>0.4</td>
<td>1.0</td>
<td>97.6</td>
<td>845</td>
</tr>
<tr>
<td></td>
<td>Saquinavir/r</td>
<td>0.4</td>
<td>0.6</td>
<td>0.2</td>
<td>98.8</td>
<td>845</td>
</tr>
<tr>
<td></td>
<td>Tipranavir/r</td>
<td>0.0</td>
<td>0.2</td>
<td>0.4</td>
<td>99.4</td>
<td>845</td>
</tr>
</tbody>
</table>

Drug resistance is an important guide to medical providers in determining the best treatment regimen for a person newly diagnosed with HIV. The genotype test gives the drug resistance profile of the particular type of virus the person has and if there are medications that will not be effective with the virus. HIV can become resistant to some medications, usually when a person does not consistently take their medication. While current treatment guidelines* specify that a genotypic resistance test should be conducted at the time of HIV diagnosis prior to starting antiretroviral therapy, only 51.1% of new HIV cases diagnosed in 2018 had a documented genotype test within 3 months of diagnosis. Ensuring that newly diagnosed HIV cases receive genotypic resistance testing is not only important for clinical practice, but is also essential for monitoring trends in drug resistance at the population level.
The dominant subtype among cases in DC is subtype B, which accounts for 90.6% of available genotype sequences. The largest proportions of high level resistance were found for Nevirapine (10.6%) and Efavirenz (9.6%). The smallest proportions of resistance were found in the protease inhibitors drug class with resistance ranging from 0%-1.1%. Additional information about drug resistance can be found in Appendix A under *Understanding HIV-related Drug Resistance*. *

**Table 3. Primary Cause of Death among People Diagnosed with HIV, by Year of Death, District of Columbia, 2013-2017**

<table>
<thead>
<tr>
<th>Cause of Death</th>
<th>2013 N</th>
<th>2013 %</th>
<th>2014 N</th>
<th>2014 %</th>
<th>2015† N</th>
<th>2015† %</th>
<th>2016 N</th>
<th>2016 %</th>
<th>2017 N</th>
<th>2017 %</th>
<th>Total N</th>
<th>Total %</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-related causes</td>
<td>92</td>
<td>34.5</td>
<td>73</td>
<td>26.6</td>
<td></td>
<td></td>
<td>91</td>
<td>28.7</td>
<td>86</td>
<td>28.5</td>
<td>399</td>
<td>27.1</td>
</tr>
<tr>
<td>Non-AIDS Defining</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignancies</td>
<td>50</td>
<td>18.7</td>
<td>45</td>
<td>16.4</td>
<td>N/A</td>
<td>N/A</td>
<td>48</td>
<td>15.1</td>
<td>50</td>
<td>16.6</td>
<td>224</td>
<td>15.2</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>37</td>
<td>13.9</td>
<td>45</td>
<td>16.4</td>
<td>N/A</td>
<td>N/A</td>
<td>45</td>
<td>14.2</td>
<td>58</td>
<td>19.2</td>
<td>229</td>
<td>15.5</td>
</tr>
<tr>
<td>Substance Use</td>
<td>1</td>
<td>0.4</td>
<td>3</td>
<td>1.1</td>
<td>N/A</td>
<td>N/A</td>
<td>3</td>
<td>0.9</td>
<td>2</td>
<td>0.7</td>
<td>13</td>
<td>0.9</td>
</tr>
<tr>
<td>Accidental Death</td>
<td>12</td>
<td>4.5</td>
<td>20</td>
<td>7.3</td>
<td>N/A</td>
<td>N/A</td>
<td>39</td>
<td>12.3</td>
<td>39</td>
<td>12.9</td>
<td>132</td>
<td>9.0</td>
</tr>
<tr>
<td>Other*</td>
<td>47</td>
<td>17.6</td>
<td>54</td>
<td>19.7</td>
<td>N/A</td>
<td>N/A</td>
<td>62</td>
<td>19.6</td>
<td>47</td>
<td>15.6</td>
<td>246</td>
<td>16.7</td>
</tr>
<tr>
<td>Unknown</td>
<td>28</td>
<td>10.5</td>
<td>34</td>
<td>12.4</td>
<td>N/A</td>
<td>N/A</td>
<td>29</td>
<td>9.1</td>
<td>20</td>
<td>6.6</td>
<td>230</td>
<td>15.6</td>
</tr>
<tr>
<td>Total</td>
<td>267</td>
<td>100.0</td>
<td>274</td>
<td>100.0</td>
<td>N/A</td>
<td>N/A</td>
<td>317</td>
<td>100.0</td>
<td>302</td>
<td>100.0</td>
<td>1,473</td>
<td>100.0</td>
</tr>
</tbody>
</table>

*2015 cause of death is incomplete and will be updated when available.

* Other causes of death include suicide, pneumonia, COP, diabetes, etc

Over 70% of deaths among people diagnosed with HIV in the District were due to non-HIV related causes between 2013 and 2017. The primary cause of death was unknown for 15.6% of deaths during this 5-year period. People diagnosed with HIV who died in 2015 had an incomplete cause of death and were not included in this report.

Please refer to appendix table B13 for additional data regarding deaths among people diagnosed with HIV disease.
Sexually Transmitted Infections

Chlamydia

9,007
Number of diagnoses reported in 2018

1.3%
of DC residents acquired Chlamydia in 2018

6%
of people diagnosed with Chlamydia in 2018 were living with HIV

12%
Of DC residents diagnosed with Chlamydia in 2018 had an STI in the previous year

Rate of Newly Reported Chlamydia Diagnoses, by Census Tract, District of Columbia, 2018 (N=9,007)

Newly Reported Diagnoses of Chlamydia, by Year, District of Columbia, 2014-2018

Number of Reported Diagnosis

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>5,730</td>
<td>7,458</td>
<td>7,955</td>
<td>9,446</td>
<td>9,007</td>
</tr>
<tr>
<td>Growth</td>
<td>57%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Of those newly reported with Chlamydia in DC in 2018...

1 in 2 were Women

1 in 2 were under the age of 25

Rates were calculated using the 2017 Census Estimates

Please refer to appendix table B14 for additional data regarding newly diagnosed Syphilis cases.
Gonorrhea

4,249

0.6%

14%

17%

Number of diagnoses reported in 2018

of DC residents acquired Gonorrhea in 2018

of people diagnosed with Gonorrhea in 2018 were living with HIV

Of people diagnosed with Gonorrhea in 2018 had an STI in the previous year

Rate of Reported Gonorrhea Diagnoses, by Census Tract, District of Columbia, 2018, (N=4,249*)

Newly Reported Diagnoses of Gonorrhea, by Year, District of Columbia, 2014-2018

Number of Reported Diagnosis

2014 2015 2016 2017 2018

2,208 2,627 3,570 4,715 4,249

92% increase

Of those newly reported with Gonorrhea in DC in 2018...

1 in 4 were aged 25-29

7 in 10 were Men

Rate of Gonorrhea per 100,000 persons

0-274.8

274.9-622.1

622.2-882.7

882.8-1,318.4

1,318.5-2218.7

*10% of cases had a missing address or an address that did not geocode and were not included in this map

Rates were calculated using the 2017 Census Estimates

Please refer to appendix table B15 for additional data regarding newly diagnosed Syphilis cases.
Syphilis

Number of primary or secondary Syphilis diagnoses reported in 2018

Of people diagnosed with Syphilis were living with HIV

Of people diagnosed with Syphilis in 2018 had another STI within the past year

The number of congenital cases diagnosed in 2018

Rate of Reported Primary and Secondary Syphilis Diagnoses, by Census Tract, District of Columbia, 2018 (N=282*)

Newly Reported Diagnoses of Primary and Secondary Syphilis, by Year, District of Columbia, 2014-2018

Of those newly reported with Primary and Secondary Syphilis in DC in 2018...

9 in 10 were Men

1 in 3 were aged 30-39

Rates were calculated using the 2017 Census Estimates

Please refer to appendix table B16 for additional data regarding newly diagnosed Syphilis cases.
Viral Hepatitis

Hepatitis B

Number of newly reported chronic Hepatitis B cases between 2014-2018

1,858

Rate of Chronic Hepatitis B in 2018 per 100,000 persons

58.6

Of all reported Chronic Hepatitis C Cases in DC between 2014-2018...

2 in 3 were Men

1 in 4 were aged 30-39

Rate of Newly Reported Chronic Hepatitis B Cases, by Census Tract, District of Columbia, 2014-2018, N=1,858

Newly Reported Chronic Hepatitis B Cases by Year, District of Columbia, 2014-2018, N=1,858

Rates were calculated using the 2017 Census Estimates

Please refer to appendix table B18 for additional data regarding diagnosed Hepatitis B cases.
Hepatitis C

16,375

Number of all positive chronic Hepatitis C cases between 2014-2018

7,054

Number of newly reported chronic Hepatitis C cases between 2014-2018

Of all reported Chronic Hepatitis C Cases in DC between 2014-2018...

2 in 3 were Men

9 in 10 were aged 50 and older

8 in 10 were born between 1945 and 1965

Newly Reported Chronic HCV Cases by Birth Cohort and Year of Diagnosis, District of Columbia, 2014-2018, N=7,054

Newly Reported Chronic Hepatitis C Cases by Year, District of Columbia, 2013-2017, N=7,054

Distribution of All* Reported Chronic HCV Cases by Current Age, District of Columbia 2014-2018 N=16,375

0.3% 0.1% 0.1% 2.1% 4.9%

62.4% 24.6%

≤ 12 13-19 20-29 30-39 40-49 50-59 ≥ 60 Unknown

* Includes both newly and previously diagnosed cases with a reported positive HCV test between 2014 and 2018

Please refer to appendix table B19-20 for additional data regarding diagnosed Hepatitis C cases.
Chronic Hepatitis C Cure Cascade

While hepatitis surveillance and case investigation activities are currently limited, efforts have been made toward utilizing available data and resources to better understand care and treatment dynamics among individuals diagnosed with chronic hepatitis C (HCV). Based on current surveillance data, 76% of individuals reported to DC Health as having chronic HCV between 2014 and 2018 had a documented positive HCV RNA confirmatory test. Of those having a positive HCV confirmatory test, 24% had evidence of an undetectable viral load based on the last reported HCV RNA laboratory result. Both percentage points provide preliminary evidence that there are opportunities to enhance care linkage and engagement activities within the District in relation to addressing the treatment needs of people with chronic HCV.

HCV Cure Cascade, District of Columbia 2014-2018
Tuberculosis

Tuberculosis (TB) is caused by the bacteria *Mycobacterium tuberculosis*. TB is spread from person to person through the air where infection can occur by sharing airspace for an extended period of time in an enclosed setting such as one's home or in a small office. TB usually affects the lungs, and bacteria are put into the air when a person with active TB of the lungs coughs, sneezes, laughs, or sings. TB can also affect other parts of the body (extrapulmonary TB). TB can be cured if treated properly.

Please refer to appendix table B17 for additional data regarding newly diagnosed HIV cases.
Special Populations

Women

- Number of Women in DC known to be living with HIV: 3,223
- Number of new HIV diagnoses in DC in 2018: 76
- Percent of women living in DC known to be living with HIV: 1.0%
- Proportion of Chlamydia diagnoses among women living in DC in 2018: 1.3%
- Number of HIV positive women who gave birth in 2018: 53

<table>
<thead>
<tr>
<th>Stage of HIV Disease at First Lab in DC and in 2018 among Women Living in DC, District of Columbia, N=3,223</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage in DC</td>
</tr>
<tr>
<td>Living in DC in 2017</td>
</tr>
<tr>
<td>4%</td>
</tr>
</tbody>
</table>

Of those newly diagnosed with HIV in DC in 2018...

- 9 in 10 were Black
- 1 in 4 were aged 30-39
Men who have Sex with Men

Number of Men who have sex with men in DC known to be living with HIV

5,540

26%

Proportion of new HIV diagnoses in 2018 with a mode of transmission of MSM among those aged 13-24

Number of New HIV Diagnoses among MSM, by Year, District of Columbia, 2014-2018

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of Reported Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>208</td>
</tr>
<tr>
<td>2015</td>
<td>210</td>
</tr>
<tr>
<td>2016</td>
<td>184</td>
</tr>
<tr>
<td>2017</td>
<td>196</td>
</tr>
<tr>
<td>2018</td>
<td>172</td>
</tr>
</tbody>
</table>

Care Dynamics among MSM Diagnosed with HIV Living in DC, 2018

- Living in DC in 2017: 5,421
- Ever linked to care: 5,361 (99%)
- Received care in 2018: 4,134
- Virally suppressed in 2018: 3,601

Stage of HIV Disease at First Lab in DC and in 2018 among MSM Living in DC, District of Columbia, N=5,421

- First Stage in DC: 1%
- Stage 2: 32%
- Stage 3 (AIDS): 34%
- Not Reported: 33%

- Stage 2018: 29%
- Stage 2: 6%
- Stage 3 (AIDS): 20%
- Not Reported: 46%

Of those newly diagnosed with HIV in DC in 2018...

- 2 in 3 were Black
- 1 in 8 were White
- 1 in 3 were aged 30-39
People Who Inject Drugs (PWID)

- **1,193** People Who Inject Drugs (PWID) known to be living with HIV in 2018
- **9** new HIV diagnoses in DC in 2018
- **31%** Proportion of HIV/HCV co-occurrence among PWID living in DC in 2018

**Newly Diagnosed PWID and the Number of Needles Exchanged, by Year, District of Columbia, 2008-2018**

**Care Dynamics among PWID Diagnosed with HIV Living in DC, 2018**
- **1,198** Living in DC in 2017
- **1,185** Ever linked to HIV care
- **762** Retained in any care in 2018
- **76% >1 medical visit**
- **99% ever linked**
- **825** Virally suppressed

**Stage of HIV Disease at First Lab in DC and in 2018 among PWID Living in DC, District of Columbia, N=1,193**

- **First Stage in DC**
  - Stage 1: 1%
  - Stage 2: 45%
  - Stage 3: 28%
  - Not reported: 16%

- **Stage in 2018**
  - Stage 1: 20%
  - Stage 2: 25%
  - Stage 3: 45%
  - Not reported: 10%
Transgender People

- 245 transgender individuals in DC known to be living with HIV in 2018
- 13 transgender men newly diagnosed between 2014-2018
- 32% proportion of new diagnoses that were aged 25-29 between 2014-2018

Stage of Disease at First Lab in DC and in 2018 among Transgender People Living in DC, District of Columbia, N=235

- 2% First Stage in DC
- 32% Stage in 2018
- 31% Stage 2
- 35% Stage 3 (AIDS)
- 22% Not reported

Care Dynamics among Transgender People Diagnosed with HIV Living in DC, 2018

- 235 living in DC in 2017
- 230 ever linked to HIV care
- 192 retained in care in 2018
- 160 virally suppressed in 2018

- 98% ever linked
- 73% >1 medical visit
- 29% 1 medical visit
- 68% suppressed

Number of New HIV Diagnoses among Transgender People, by Year, District of Columbia, 2014-2018, N=48

- 2014: 13
- 2015: 10
- 2016: 10
- 2017: 6
- 2018: 9
## Older Adults (Aged 55 and older)

### Number of individuals aged 55+ known to be living with HIV

<table>
<thead>
<tr>
<th>Stage of HIV Disease</th>
<th>First stage in DC</th>
<th>Stage in 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Living in DC in 2017</td>
<td>4076</td>
<td>4027</td>
</tr>
<tr>
<td>Ever linked to HIV care</td>
<td>58%</td>
<td>24%</td>
</tr>
<tr>
<td>Retained in any care in 2018</td>
<td>76% &gt;1 medical visit</td>
<td>70% suppressed</td>
</tr>
<tr>
<td>Virally suppressed in 2018</td>
<td>70%</td>
<td></td>
</tr>
</tbody>
</table>

### Of those newly diagnosed with HIV in DC in 2014-2018...

- 7 in 10 were Black
- 3 in 5 were men
- 6 in 10 had a mode of transmission of sexual contact

### Number of Newly Reported HIV, Chlamydia, Gonorrhea and P&S Syphilis Diagnoses among People aged 55+, by Year, District of Columbia, 2014-2018

- HIV Disease
- Chlamydia
- Gonorrhea
- Syphilis
Foreign-born People

Number of foreign-born people living with HIV in DC at the end of 2018: 898
Number of foreign-born people newly diagnosed with HIV between 2014-2018: 290

Of all foreign-born Persons diagnosed in DC in 2018...
- 6 in 10 were Black
- 1 in 3 were aged 25-29
- 2 in 3 were Men

Stage of HIV Disease at First Lab in DC and in 2018 among Foreign-born People Living in DC, District of Columbia, N=860

Care Dynamics among Foreign-born People Diagnosed with HIV Living in DC, 2018
- 39% of cases linked to care
- 64% virally suppressed in 2018

Number of New HIV Diagnoses among Foreign-born People, by Year, District of Columbia, 2014-2018

- 2014: 46 cases, 2.2% Male, 69.6% Female, 28.3% Transgender
- 2015: 76 cases, 60.5% Male, 35.8% Female, 2.6% Transgender
- 2016: 83 cases, 66.3% Male, 32.5% Female, 1.2% Transgender
- 2017: 56 cases, 66.1% Male, 33.9% Female, 3.5% Transgender
- 2018: 29 cases, 62.1% Male, 34.5% Female, 3.5% Transgender
National HIV Behavioral Surveillance Study (NHBS)

Men who have Sex with Men

The National HIV Behavioral Surveillance (NHBS) is a CDC-funded initiative to learn more about what puts people at risk for HIV. The purpose of NHBS is to assess prevalence of HIV and trends in sexual and drug-use behaviors among populations most at risk for HIV. In 2017, men who have sex with men were recruited from several venues throughout the DC Metropolitan Statistical Area (MSA) and were surveyed.

Among those that tested HIV positive, 1 in 5 men were considered new positives.

Black MSM had the highest rate of HIV infection:

- Other*: 22%
- Latinx: 28%
- White: 10%
- Black: 37%

Nearly 7 in 10 men had condomless anal sex at last sexual encounter.

More than half of men reported that they had a concurrent sex partner in the last 12 months.

HIV and STD Testing and Missed Opportunities

71% of men who saw a healthcare provider were offered an HIV test.

Self-reported STI prevalence in the last 12 months varied:

- Gonorrhea: 16%
- Chlamydia: 11%
- Syphilis: 7%

Rectal Gonorrhea and Chlamydia prevalence among study participants:

- Gonorrhea: 4%
- Chlamydia: 10%

Anti-HIV Drug Knowledge and Use

- 94% of men heard of anti-HIV medication (PrEP)
- 56% of men had a discussion with the healthcare provider about PrEP
- 50% of men reported PrEP use in the last 12mo
- Among men who used PrEP in the last 12mo, 59% reported never/rarely using condoms during sex
- Among self-reported HIV positive men, 72% reported that their HIV-negative partner was taking PrEP
- 5% of men reported taking anti-HIV medication (PrEP) after sex in the last 12mo